The approval of aflibercept for the neovascular form of age-related macular degeneration has opened up the possibility of treating patients with fewer injections, since the drug can be administered once every two months. Aflibercept can also be used as rescue therapy in patients with suboptimal response to other antiangiogenic treatments. The present study reviews the scientific evidence on aflibercept, both in treatment-naïve patients and in those with an unsatisfactory response to conventional treatments.
Keywords: Aflibercept; Age-related macular degeneration; Choroidal neovascularization; Degeneración macular asociada a la edad Neovascularización coroidea; Ranibizumab; Respondedores subóptimos; Suboptimal responders.
Copyright © 2015 Sociedad Española de Oftalmología. Published by Elsevier España, S.L.U. All rights reserved.